RFP
RCUS icon

Root Financial Partners’s Arcus Biosciences RCUS Stock Holding History

Root Financial Partners’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40
Closed -$864 – 2526
2026
Q1 		$864 Buy
+40
New +$864 ﹤0.01% 2667

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Root Financial Partners's RCUS Position: Q2 2026 in Review

Root Financial Partners sold out of Arcus Biosciences (RCUS) in Q2 2026, closing a stake of 40 shares — an estimated $864 sold.

Root Financial Partners first reported a position in RCUS in Q1 2026 and held it in 1 quarter. The position peaked at $864 in Q1 2026. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Root Financial Partners reported no remaining Arcus Biosciences position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 40 Arcus Biosciences shares in Q2 2026, an estimated $864.
  • Root Financial Partners first reported a position in Arcus Biosciences in Q1 2026 and held it in 1 quarter.
  • Root Financial Partners's Arcus Biosciences position peaked at $864 in Q1 2026.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.